Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease.

Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease.   Lead oral compounds demonstrated up to 25% body weight reduction with preferential fat loss, preserved lean mass, and broad metabolic improvements in DIO models Boston, MA —  June 25th 2026  —  (GLOBENEWSWIRE) Mwyngil Therapeutics, […]

Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio

Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio Dover, DE – February 2nd, 2026 (PR Newswire) — Mwyngil Therapeutics, a clinical-stage biopharmaceutical company focused on immunometabolic and neuroinflammatory diseases, today announced the initiation of a Phase 1 clinical study of BT-409, a potentially best-in-class, brain-permeable NLRP3 inhibitor being developed for multiple sclerosis (MS), Parkinson’s disease (PD), and […]

Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.

Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc. Dover, DE – November 6, 2025 (PR Newswire) — Mwyngil Therapeutics Inc., a biopharmaceutical company dedicated to developing first-in-class and best-in-class small-molecule therapies targeting cardiovascular, metabolic, and chronic inflammatory and immune diseases, today announced the in-licensing of several lead GPR75 modulator molecules […]